CHRNChronoScale Corporation
Price
+201%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growth fading, the market undecided.
We operate our business through two wholly-owned subsidiaries: ChronoScale Corporation, a Nevada corporation (f/k/a Applied Digital Cloud Corporation, a Nevada corporation) (“Cloud”), and Ekso Bionics, Inc., a Delaware corporation (“Legacy Ekso”). Following the Holding Company Transaction (as defined and described below), Applied Digital Cloud Corporation changed its name to ChronoScale Corporation. All references to “Cloud” prior to the Holding Company Transaction are to Applied Digital Cloud Corporation and after the Holding Company Transaction, to ChronoScale Corporation.
In the company’s own words · 10-K filed Aug 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
ChronoScale Corporation (CHRN) reported revenue of $41M in Q1 2027 (quarter ended Aug 31, 2026), up 881% from the same quarter a year earlier. That came with a gross margin of −10.0% and net loss of $42M. For the full year FY2026, revenue was $72M (+299% year on year) and net income −$50M. Its largest region in Q1 2026 (quarter ended Mar 31, 2026) was United States at $1.5M, 87% of the disclosed total, well ahead of France at 12%. The next results filing is expected around Jan 14, 2027, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 15, 2026Reports Fiscal First Quarter 2027 Results.Earnings release · press release
- Oct 6, 2026Davis As previously announced, on September 30, 2026, ChronoScale Holdings Corporation, a Nevada corporation (the “Company”) completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc. (“Ekso”)Director or officer change · Form 8-K
- Oct 2, 2026Separation and Severance Agreement with Mr. Jones On September 30, 2026, ChronoScale Holdings Corporation, a Nevada corporation (the “Company”) completed the sale of its wholly owned subsidiary, Ekso Bionics, Inc. (“Ekso”) (the “Transaction”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q1 2026 · $1.8MThe company’s own SEC segment disclosure.
- United States$1.5M87%
- France$207.0K12%
- Italy$26.0K1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Information Technology Services
Ranks #27 of 30 by RyuScore